Scarica l'app Stockscreener
103.16
2.92%
-2.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$106.03
Aprire:
$104.09
Volume 24 ore:
1.47M
Relative Volume:
0.52
Capitalizzazione di mercato:
$22.30B
Reddito:
$819.56M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-17.96
EPS:
-5.7434
Flusso di cassa netto:
$-951.64M
1 W Prestazione:
-5.46%
1M Prestazione:
-22.76%
6M Prestazione:
-50.18%
1 anno Prestazione:
+43.60%
Intervallo 1D:
$100.56
$104.45
Intervallo di 1 settimana:
$100.56
$109.95
Portata 52W:
$70.57
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
102.91 | 22.98B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
426.51 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
595.61 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.78 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.21 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.83 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-03-30 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
A Look At Insmed (INSM) Valuation After Recent Share Price Weakness And Brensocatib Launch Expectations - Yahoo Finance
ATS 2026: Insmed shines in bronchiectasis with spotlight on Brinsupri - Yahoo Finance
Rhenman & Partners Asset Management AB's Insmed Inc(INSM) Holding History - GuruFocus
Goldman Sachs healthcare conference brings Insmed to 2026 Miami stage - Stock Titan
Insmed CEO defends BRINSUPRI launch as sales surge, TPIP pipeline gains focus - MSN
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
Insmed (INSM) Slides 3% as Investors Weigh Recent Shelf Registration and Post-earnings Reset - Moomoo
Insmed chief legal officer Michael Smith sells $666,982 in shares By Investing.com - Investing.com India
FRANKLIN SMALL CAP GROWTH FUND's Insmed Inc(INSM) Holding History - GuruFocus
Insider Sell Alert: Michael Smith Sells 6,149 Shares of Insmed I - GuruFocus
Insmed chief legal officer Michael Smith sells $666,982 in shares - Investing.com
Insmed (INSM) slides 3% as investors weigh recent shelf registration and post-earnings reset - Quiver Quantitative
INSM: Michael Smith (INSM) files Form 144 reporting share dispositions - Stock Titan
Insmed Insider Sold Shares Worth $666,982, According to a Recent SEC Filing - Moomoo
Insmed (INSM) legal chief sells 6,149 shares under Rule 10b5-1 plan - Stock Titan
Insmed (INSM) CEO sells shares, exercises options under 10b5-1 plan - Stock Titan
TD Cowen Initiates Insmed(INSM.US) With Buy Rating, Announces Target Price $243 - Moomoo
Competitive Pressures Prompt Truist to Cut Target on Insmed (INSM) - Insider Monkey
INSM, FSLR, APTV: Dreaded death cross has formed on these stocks — what it means for investors - MSN
11 Best Long Term US Stocks to Buy Right Now - Insider Monkey
Assessing Insmed (INSM) Valuation After Recent Share Price Pullback And Strong Multi Year Returns - Yahoo Finance
Insmed's Q1 earnings beat, sales miss estimates, stock tanks 23% - MSN
William Blair Maintains Insmed(INSM.US) With Buy Rating - Moomoo
Analyst Reaffirms Buy on Insmed, Citing Strong ENCORE Phase IIIb Arikayce Data and TPIP IPF Upside - TipRanks
William Lewis lists proposed INSM share sales (05/2026) — INSM - Stock Titan
Insmed To Present at March 2026 Investor Conferences - GuruFocus
UBS Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $166 - Moomoo
Insmed, Inc. $INSM Shares Purchased by iA Global Asset Management Inc. - MarketBeat
Insmed Incorporated (INSM): Investor Outlook Reveals 84% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus - sharewise.com
AustralianSuper Pty Ltd Takes $1.74 Million Position in Insmed, Inc. $INSM - MarketBeat
Insmed CFO Sara Bonstein sells $961k in company stock - Investing.com UK
Insmed Inc files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Insmed Inc Files For Mixed Shelf Offering Size Not DisclosedSEC Filing - TradingView
Insmed (NASDAQ: INSM) files shelf registration to enable future stock and debt offers - Stock Titan
Darwin Global, affiliates hold 7.8% of INSMED (INSM) in 13G/A filing - Stock Titan
Insmed CFO Sara Bonstein sells $961k in company stock By Investing.com - Investing.com South Africa
Insmed Insiders Sold Shares Worth Over $3.2M - TradingView
Insmed (NASDAQ: INSM) director awarded 3,305 RSUs, now holds 246,081 shares - Stock Titan
Insmed (INSM) CFO sells 8,272 shares to cover RSU tax obligations - Stock Titan
Insmed (INSM) director Carol Schafer awarded 3,305 RSUs in equity grant - Stock Titan
INSMED (INSM) COO Roger Adsett sells 5,837 shares to cover RSU taxes - Stock Titan
Insmed (INSM) director granted 3,305 RSUs vesting after one year - Stock Titan
Insmed (NASDAQ: INSM) CMO sells 18,333 shares under Rule 10b5-1 plan - Stock Titan
Insmed (INSM) legal chief sells 4,109 shares to cover RSU taxes - Stock Titan
INSMED Inc (INSM) director Brennan receives 3,305 RSUs and reports 124,238 total shares - Stock Titan
Insmed (NASDAQ: INSM) director receives 3,305 RSUs equity award - Stock Titan
Director Leo Lee (NASDAQ: INSM) receives 3,305 RSUs equity grant - Stock Titan
INSMED (INSM) CEO Lewis sells 13,283 shares to cover RSU tax obligations - Stock Titan
Insmed (NASDAQ: INSM) investors approve board picks, pay and auditor - Stock Titan
NYLI Fiera SMID Growth Fund's Insmed Inc(INSM) Holding History - GuruFocus
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):